α7 nicotinic acetylcholine receptors in lung cancer (Review)

SHENGCHAO WANG[1] and YUE HU[2]

[1]Department of Gynecological Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou; [2]Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China

Received November 23, 2017; Accepted April 27, 2018

DOI: 10.3892/ol.2018.8841

Abstract. Lung cancer has one of the highest mortality rates among malignancies globally, and smoking has been documented as the main cause of lung cancer. Nicotinic acetylcholine receptors (nAChRs) were initially identified as notable regulators of the nervous system. In addition to their function in the brain, accumulating evidence indicates that nAChRs perform a host of diverse functions in almost all non-neuronal mammalian cells. The homomeric α7nAChR, a subtype of nAChRs, is responsible for the proliferative, pro-angiogenic and pro-metastatic effects of nicotine in lung cancer. Provided the association of cigarette smoking with several disease types such as cardiovascular disease, the α7nAChR-mediated signaling pathway has been implicated in the pathophysiology of lung cancer. Currently, strategies that target the α7nAChR including α7nAChR antagonists are considered to be potentially useful anticancer drugs for therapeutic purposes. Thus, the present review assesses current understanding of the function and underlying molecular mechanisms of α7nAChR in lung cancer and evaluates how targeting α7nAChR may result in novel therapeutic methods.

Contents

Correspondence to: Dr Yue Hu, Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang 310009, P.R. China
E-mail: huyue88@zju.edu.cn

Abbreviations: nAChRs, nicotinic acetylcholine receptors; NNK, nicotine-derived nitrosamines 4-(methylnitrosamino)-1-(3-pyrydyl)-1-butanone; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer; α-CbT, α-cobratoxin

Key words: α7 nicotinic acetylcholine receptor, lung cancer, nicotine, proliferation, angiogenesis, metastasis

1. Introduction

Lung cancer is one of the most commonly occurring carcinoma types globally and has limited treatment options for advanced-stage disease (1). Lung cancer is a heterogeneous disease comprised of two main pathological types: Non-small-cell lung cancer (NSCLC) which accounts for 70-80% of all lung cancer cases and small-cell lung cancer (SCLC) which accounts for ~20% of all lung cancer cases (2). NSCLCs may be divided into three subtypes: Squamous-cell carcinoma (25-30% of all lung cancer cases), adenocarcinoma (~40% of all lung cancer cases) and large-cell carcinoma (10-15% of all lung cancer cases) (3). SCLC is the second most prevalent form of lung cancer, with a 5-year survival rate of <7% (4). Cigarette smoking is considered to be the main risk factor for lung cancer, and ~90% of all cases are associated with exposure to smoking and second-hand smoking (5). Other contributory factors include residential radon, occupational hazards including exposure to asbestos, arsenic and polycyclic aromatic hydrocarbons, radiation, coal smoke, indoor emission of fuel burning, outdoor pollution, previous non-malignant lung diseases in addition to a family history of tumors (6,7). Squamous-cell, large-cell and SCLC are the most commonly identified types of lung cancer present in smokers (8,9). In contrast, adenocarcinoma is the lung cancer type most commonly identified in non-smokers (10).

Cigarette smoke is a mixture of thousands of chemical compounds, a number of which have potent carcinogenic potential including polycyclic aromatic hydrocarbons, nicotine and the nicotine-derived nitrosamines 4-(methylnitrosamino)-1-(3-pyrydyl)-1-butanone (NNK) and N-nitrosonornicotine (11). The most harmful and addictive component is nicotine (11). These carcinogens and their metabolites may induce the formation of DNA adducts which result in mutations of a number of key cancer suppressor genes, including retinoblastoma tumor suppressor protein (Rb), KRAS proto-oncogene, GTPase and tumor protein p53 (11) and eventually contributing to tumorigenesis in different ways. Accumulating evidences have suggested that nicotine not only contributes to tumorigenesis but may also increase the spread of cancer in the body (12-14).

It has been demonstrated that nicotine exerts its biological effects through nicotinic acetylcholine receptors (nAChRs) in human lung cancer cells (15). nAChRs are pentameric proteins composed of homologous subunits, which are encoded by a large multigene family (16,17). This receptor family was initially identified as notable regulators of the nervous system (18). In addition to their function in neuromuscular and motor autonomous transmission, nAChRs perform numerous central functions in almost all non-neuronal mammalian cells (18). The α7 subtype (α7nAChR), a subtype of nAChRs, is expressed in a variety of cells, including in endothelial cells, glial cells, brain radial glial cells, synovial cells and thymus cells, lymphocytes, bone marrow cells, monocytes, macrophages and microglia (19-21). Numerous studies have revealed that α7nAChR serves a notable function in the oncogenic process (22-24). In accordance with this notion, α7nAChR has been implicated in the proliferative, pro-angiogenic and pro-metastatic effects of nicotine in lung cancer types (24-27). Therefore, the α7nAChR-associated signaling networks in tumor cells may represent a novel target for the therapy of nicotine-associated lung cancer types.

The present review overviews evidence of previous studies to demonstrate the effects and molecular mechanisms of α7nAChR in lung cancer, and then describes the potential association of these signaling pathways with cancer-associated processes.

2. Epidemiology of lung cancer

Lung cancer is one of most deadly carcinoma types globally (28,29). Despite improvements in the diagnosis and treatment of this malignancy in previous years, the incidence and mortality rates of lung cancer are increasing. Based on Globocan 2012 estimates, lung cancer is the most commonly occuring cancer type among men in developed and developing countries and has exceeded breast cancer as the leading cause of cancer mortality amongst women in developed countries (30). In 2012, a total of ~1.8 million people were affected by this disease, and the estimated mortality rate was 1,098,700 and 491,200 for men and women, respectively (31). Amongst men, the highest lung cancer incidence rates were in Europe, Eastern Asia and Northern America, while the lowest incidence rates were in sub-Saharan Africa. Amongst women, the highest lung cancer rates were in Northern America, Northern and Western Europe, Australia/New Zealand and Eastern Asia (31). In China, lung cancer is the most commonly occurring cancer and the leading cause of cancer-associated mortality (32). Notably, this disease has one of the worst prognoses of all malignant tumor types and the overall 5-year survival rate is ~17.8% (33). Therefore, it is important to develop novel effective strategies in treatment of lung cancer.

Smoking is a key risk factor for lung cancer. The increase in lung cancer incidence globally parallels the rise of cigarette consumption (34). Particularly of note is that smoking is associated with 90% of SCLC and 60% of NSCLC cases and is responsible for ~80% of lung cancer mortality (35). A previous analysis revealed that passive smoking resulted in a higher risk of developing lung cancer compared with non-smokers (36). According to the U.S. Surgeon General, the risk of lung cancer in a non-smoker living with a smoker may be increased by 20-30% compared with a non-smoker living without a smoker (37). Notably, in countries where the tobacco epidemic has been established more recently, including in China, Indonesia and several countries in Africa, lung cancer rates are expected to continue to increase at least for the next few decades (38). Thus, apart from primary prevention programs including an effective tobacco-control policy, novel target molecules and the potential mechanisms of tobacco-associated lung cancer may attract more attention and should be further evaluated in future studies.

3. Expression of α7nAChR in lung cancer

Previous studies have revealed that nicotine-mediated tumor progression is initiated through the activation of nAChRs, specifically the α7 subunit (39-42). nAChRs belong to the superfamily of ligand-gated ion channels, including the excitatory $5HT_3$ receptor and the inhibitory receptors for glycine and γ-aminobutyric acid (43). To date, a number of nAChRs comprising various combinations of subunits have been identified (α1-α10, β1-β4, γ, δ and ε) (16,17). These receptors are activated by tumor cells contributing to the initiation of the non-adrenergic, non-cholinergic signaling, thereby promoting proliferation, angiogenesis and migration through autocrine and paracrine effects in lung cancer (44,45).

α7nAChR is expressed in several types of human lung cancer, including squamous cell lung cancer cells, lung adenocarcinoma and SCLC (11,46-49). Notably, the levels of α7nAChR expression are higher in squamous carcinoma compared with adenocarcinoma, particularly in smokers (50). In addition, there are different responses to cigarette smoking between women and men. α7nAChR expression is higher in male patients that smoked compared with female patients that smoked (51). Based on these observations, it has been proposed that α7nAChR upregulation in lung cancer cells may be involved in the nicotine-induced tumorigenic process (50,51). Future studies are required to explore the characteristics of α7nAChR which are emerging as a potential target for lung cancer therapy.

4. Roles and mechanisms of α7nAChR in lung cancer

Regulatory function of α7nAChR in lung cancer. Although nAChRs are widely expressed in non-neuronal and lung cancer cells, nicotine-mediated tumor progression is facilitated predominantly through α7nAChR (44,45). Consistent with this, α7nAChR levels have been revealed to be elevated in human squamous-cell lung cancer cells during sustained nicotine exposure (49). Similarly, the levels of α7nAChR in squamous cell carcinoma of lung tissues isolated from patients (who are active smokers) correlate with their smoking history (49). In addition, a previous study has revealed that α7nAChR levels were increased in mice that were administered nicotine (52), and nicotine-mediated effects on cell proliferation, invasion, migration and angiogenic tubule formation are abrogated in the presence of α7nAChR-specific inhibitors (53). Therefore, studying the role of α7nAChR and its underlying molecular mechanisms in lung cancer is clinically relevant.

A majority of mechanistic studies (27,47,49,51,53-69) focus on identifying the function of α7nAChR-mediated signaling

Table I. Regulatory function of α7nAChR in lung cancer.

Author, year	Targeted cell type(s)	Major outcome(s) associated with α7nAChR	(Refs.)
Zhang *et al*, 2016	NSCLCs	NSCLC cell invasion, migration and epithelial-mesenchymal transition were mediated by α7nAChR and MEK/ERK signaling pathway induced by nicotine	(27)
Dasgupta *et al*, 2006	NSCLCs	α7nAChR regulated the oncogenic process which depends on proliferation and survival-associated genes induced by nicotine	(47)
Brown *et al*, 2013	SCCLs	Upregulation of α7nAChRs accelerated tumor proliferation and progression through binding GATA4 or GATA6 stimulated by nicotine	(49)
Paleari *et al*, 2008	NSCLCs	α7nAChR promoted tumor cell growth by activating the Rb-Raf-1/phospho-ERK/phospho-$p90^{RSK}$ pathway	(51)
Medjber *et al*, 2015	NSCLCs	α7nAChR regulated cell growth and stimulated tumor invasion depending on the differentiation status of the tumor in NSCLCs	(53)
Al-Wadei *et al*, 2012	NSCLCs	α7nAChR promoted proliferation in nicotine-treated NSCLC cells by upregulating the stress neurotransmitter noradrenaline	(54)
Zovko *et al*, 2013	NSCLCs	APS8 inhibited cell growth and triggered the intrinsic apoptotic pathways	(55)
Paleari *et al*, 2009	NSCLCs (A549 cells)	α-CbT specifically inhibited the α7nAChR-mediated survival pathway	(56)
Grozio *et al*, 2008	NSCLCs (A549 cells)	α-CbT may reduce the tumor cell growth factors of nicotine	(57)
Sheppard *et al*, 2000	SCLCs	Activation of $Ca2^{+}$ influx contributed to the development of SCLCs by binding α7nAChR induced by NNK	(58)
Jull *et al*, 2001	SCLCs	NNK regulated the SCLCs growth by initiating the Raf-1/MAPK/c-myc kinase pathway i*n vitro*	(59)
Hung *et al*, 2009	CL1.0 lung cancer cells	NNK activated α7nAChR downstream signaling pathways of Akt and ERK	(60)
Zhong *et al*, 2015	NSCLCs	PGE2 increased the expression of α7nAChR by activating signals of JNK, PI3K and PKA through upregulating c-Jun	(61)
Sun *et al*, 2009	NSCLCs	Nicotine upregulated the expression of PPARβ/δ through α7nAChR-mediated activation of PI3K/mTOR signals and suppression of AP-2α protein expression and DNA binding activity in the PPARβ/δ gene promoter	(62)
Chernyavsky *et al*, 2015	SCCLs (SW900)	Activation of α7nAChR is associated with EGF and VEGF receptors in cell membrane	(63)
Brown *et al*, 2012	SCLCs	MG624 inhibited the angiogenesis of human SCLC tumor types followed by the suppression of nicotine-induced FGF2	(64)
Shen *et al*, 2012	Lung cancer cell lines (i.e. H1299, H82, H157 cells and H460 cells)	α-BTX blocked the tyrosine phosphorylation of c-Src, PKCι and FAK and prevented metastatic tumor types induced by NNK	(65)
Iskandar *et al*, 2016	Lung cancer cells	BCX restrains the migration and invasion of α7nAChR-positive lung cancer cells through the downregulation of α7nAChR/PI3K signaling	(66)
Zhang *et al*, 2017	NSCLCs (H1299)	Blocking α7nAChRs suppresses nicotine-induced H1299 cell proliferation are mediated through the de-phosphor ylation of the MEK signaling pathway in H1299 cells	(67)
Mucchietto *et al*, 2017	NSCLCs (A549 cells)	In A549 cells, α7 nAChR not only regulate nicotine-induced cell proliferation but also the activation of the Akt and ERK pathways	(68)

Table I. Continued.

Author, year	Targeted cell type(s)	Major outcome(s) associated with α7nAChR	(Refs.)
Yan *et al*, 2017	NSCLCs (A549 cells)	The methyllycaconitine citrate hydrate MLA and rL-RVG (the rabies virus glycoprotein) treatments significantly inhibited proliferation and migration and promoted apoptosis in the lung cancer cells	(69)

α7nAChR, α7 nicotinic acetylcholine receptor; NSCLC, non-small-cell lung carcinoma; SCCL, small cell carcinoma of the lung; SCLC, small-cell lung carcinoma; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinase; Rb, retinoblastoma tumor suppressor protein; Raf-1, RAF proto-oncogene serine/threonine-protein kinase; $p90^{RSK}$, MAPK-activated protein kinase-1; GATA, GATA binding protein; APS8, an analog of 3-alkylpyridinium polymers with a defined alkyl chain length and molecular size; α-CbT, α-cobratoxin; NNK, nicotine-derived nitrosamines 4-(methy lnitrosamino)-1-(3-pyrydyl)-1-butanone; MAPK, mitogen-activated protein kinase; c-myc, MYC proto-oncogene, BHLH transcription factor; Akt, protein kinase B; PGE2, prostaglandin E2; JNK, c-Jun N-terminal kinase; PI3K, phosphoinositide 3-kinase; PKA, protein kinase A; PPAR, peroxisome proliferator-activated receptors; mTOR, mammalian target of rapamycin; AP-2α, transcription factor AP-2 α; EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; MG624, an α7-nicotinic receptor antagonist; α-BTX, α-Bungarotoxin; MLA, an α7 nAChR antagonist; FGF2, fibroblast growth factor 2; c-Src, proto-oncogene tyrosine-protein kinase Src; PKCι, protein kinase Cι; FAK, focal adhesion kinase; BCX, β-cryptoxanthin.

in the regulation of the tumorigenic process including in proliferation, angiogenesis and metastasis in lung cancer (Table I). Notably, a number of α7nAChRs antagonists have been investigated to explore its influence on tumor progression (56,57,64-66,69). Provided that α7nAChR is a major genetic biomarker of nAChRs for lung cancer (70), strategies that target α7nAChR may be useful in the treatment of lung cancer for therapeutic purposes.

Function and mechanisms of α7nAChR on cell proliferation. At present, α7nAChR has been proposed to mediate nicotine-induced survival rate and proliferation in cancer cells *in vitro* and *in vivo* (22,70). It was revealed that proliferative signaling via α7nAChR required the scaffolding protein β-arrestin, while the ablation of β-arrestin or disruption of the Rb-RAF proto-oncogene serine/threonine-protein kinase (Raf-1) interaction blocked the nicotine-induced proliferation of NSCLCs (47). Furthermore, the α7nAChR-induced release of noradrenaline significantly stimulated NSCLC proliferation associated with the induction of phosphorylated (p)-extracellular signal-regulated kinases (ERK) and p-cAMP response element-binding protein signaling, suggesting that α7nAChR represents an attractive target for developing more effective intervention strategies for NSCLC (54). A previous study demonstrated that exposure to nicotine resulted in α7nAChRs upregulation in human squamous cell lung cancer via the Sp1 transcription factor/GATA binding protein pathway, which accelerates tumor proliferation and progression (49). However, several signals underlying α7nAChR-induced cell proliferation included the activation of $Ca2^{+}$ influx (58), Raf-1 (51,59), mitogen-activated protein kinase/ERK (27,51,59,60), c-Jun N-terminal kinase, phosphoinositide-3 kinase (PI3K)/protein kinase B (Akt), protein kinase A (PKA) pathway (60-62), epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) receptors (63), and mitogen-activated protein kinase kinase (MEK)/ERK (67). In nicotine-induced lung cancer cells, Chernyavsky *et al* (63) revealed that the activation of cell membrane α7nAChR resulted in the association with EGF receptors, whereas activated mitochondrial α7nAChR physically associated with the intramitochondrial protein kinases PI3K and Src. Zhang *et al* (67) demonstrated that the blockade of α7nAChR specifically inhibited nicotine-stimulated tumor growth in NSCLC through the MEK/ERK signaling pathway. It has also been reported that α7nAChRs mediate the pro-proliferative effects of nicotine through activating Akt and ERK pathways, and blocking α7nAChRs eliminates nicotine-induced proliferation and signaling in A549 cells (68). These findings indicate that the expression of α7nAChR is associated with cellular survival rate and proliferation in lung cancer. A potential strategy may be to use α7nAChR as a biomarker to inhibit tumor proliferation and progression in lung cancer. Based on this information, α7nAChRs antagonists were revealed to attenuate the proliferative effects of nicotine in lung cancer (22). An analog of 3-alkylpyridinium polymers with a defined alkyl chain length and molecular size (APS8) may inhibit tumor may inhibit tumor growth and trigger the intrinsic apoptotic pathways in NSCLCs (55). Another study has confirmed that α7nAChRs antagonists including d-tubocurarine and α-cobratoxin (α-CbT) may reduce tumor cell growth factors stimulated by



Figure 1. Role of α7nAChR on proliferation, angiogenesis and metastasis in lung cancer. α7nAChR, α7 nicotinic acetylcholine receptor; GATA, GATA binding protein; Raf-1, Raf-1 proto-oncogene, serine/threonine kinase; Sp1, Sp1 transcription factor; c-Jun N-terminal kinase; FGF2, fibroblast growth factor 2; c-Src, proto-oncogene tyrosine-protein kinase Src; PKCι, protein kinase Cι; FAK, focal adhesion kinase; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinases; PI3K, phosphoinositide 3-kinase; PKA, protein kinase A; EGFR, epidermal growth factor; VEGFR, vascular endothelial growth factor receptors.



Figure 2. Overview of the α7nAChR antagonists in lung cancer. α7nAChR, α7 nicotinic acetylcholine receptor; α-CbT, α-cobratoxin; APS8, an analog of 3-alkylpyridinium polymers with a defined alkyl chain length and molecular size; MLA, an α7 nAChR antagonist; MG624, an α7-nicotinic receptor antagonist; BCX, β-cryptoxanthin; α-BTX, α-Bungarotoxin; FGF2, fibroblast growth factor 2; PI3K, phosphoinositide 3-kinase; p-c-Src, phosphorylated proto-oncogene tyrosine-protein kinase Src; PKCι, protein kinase Cι; FAK, focal adhesion kinase.

nicotine (56,57). Yan *et al* (69) revealed that methyl lycaconitine citrate hydrate (a α7nAChR antagonist) and rabies virus glycoprotein treatments significantly inhibited proliferation and promoted apoptosis in A549 lung adenocarcinoma cells.

Function and mechanisms of α7nAChR on angiogenesis. Angiogenesis is widely known as a typical characteristic in cancer to sustain tumor growth (71). Angiogenesis is necessary for primary tumor progression (72). Surprisingly, there is a limited study focusing on the angiogenic activity of α7nAChR in lung cancer. A previous study has demonstrated that the small-molecule antagonist for α7nAChR (MG624), inhibited angiogenesis effects in SCLCs followed by the suppression of nicotine-induced fibroblast growth factor 2 (64). Since α7nAChR upregulation by cancer cells stimulates tumor progression, it can be used in future studies to further explore its effects on angiogenesis.

Function and mechanisms of α7nAChR on metastasis. Metastasis is the major cause of mortality in cancer (73). The process of metastasis may be classically divided into a number of steps: Invasion of tumor cells into the surrounding tissues, penetration of vessels and migration toward distant sites of the body away from the primary sites (74). At present, several clinical studies in humans revealed an association between smoking and an increase in the metastasis of lung cancer (75-78). The α7nAChR is expressed in SCLC and NSCLC cells (24). Nicotine has a high affinity with α7nAChR in lung cancer cells (50). Thus, it would be useful to understand the mechanism of α7nAChR in metastasis in nicotine-associated lung cancer types (79). α7nAChR may regulate cell growth and stimulate tumor invasion depending on the differentiation status of the tumor in NSCLCs (53). The pro-proliferative activity of poorly-differentiated NSCLC was stimulated by nicotine, whereas it was suppressed in well-differentiated cells (53). Nicotine may also induce NSCLC cells invasion, migration and mesenchymal transition, which were mediated by α7nAChR involving the MEK/ERK signaling pathway (27). Meanwhile, the effects induced by nicotine may be suppressed by pharmacological intervention using α7nAChR selective antagonists or by genetic intervention using α7nAChR small interfering RNAs (55,68). α-bungarotoxin appeared to be one of the specific inhibitor for α7nAChR, which blocked metastatic tumors by NNK-induced tyrosine phosphorylation of proto-oncogene tyrosine-protein kinase Src, protein kinase Cι and focal adhesion kinase (65). In addition, β-cryptoxanthin treatment restrained the migration and invasion of α7nAChR-positive lung cancer cells through the downregulation of α7nAChR/PI3K signaling (66). All the aforementioned results suggest that α7nAChR enhances the metastasis of lung cancer cells, although the underlying molecular mechanisms require further investigation.

5. Conclusions

Despite efforts that have been reported focusing on α7nAChR as a molecular target in human diseases including lung cancer, a number of issues remain be addressed in future studies: i) Currently available evidence indicates that α7nAChR activation activates signaling pathways involved in the proliferation, angiogenesis and metastasis for developing lung cancer (Fig. 1), and thus it is crucial to analyze the difference of α7nAChR expression and underlying mechanisms in SCLC and NSCLC cells; ii) Little is known on the roles of these pathways in cell types including macrophages and other immune cells which are also very important in tumorigenesis; iii) α7nAChR expression is activated in the process of nicotine-mediated cancer; however, how α7nAChR antagonists (e.g., α-CbT treatment) are regulated in lung cancer is uclear (Fig. 2). Nevertheless, although there are several limitations for α7nAChR-based drug therapy for clinical use for lung cancer or other diseases, these potential mechanisms are inevitably the foundation of designing novel anticancer drugs in lung cancer.

Acknowledgements

Not applicable.

Funding

This study was supported by the Medical and Health Science Technology plan project of Zhejiang province, China (no. 2017KY431).

Availability of data and materials

Not applicable.

Authors' contributions

SCW and YH conceived and wrote the paper. YH reviewed and made final approval of the version to be published. All authors read and approved the manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Schwartz AG and Cote ML: Epidemiology of lung cancer. Adv Exp Med Biol 893: 21-41, 2016.
2. Sher T, Dy GK and Adjei AA: Small cell lung cancer. Mayo Clin Proc 83: 355-367, 2008.
3. Kuribayashi K, Funaguchi N and Nakano T: Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma. J Cancer Res Ther 12: 528-534, 2016.
4. Li J, Zhao Y, Li C, Zhu L, Liu C and Liu L: The revision of 8th edition TNM stage criteria is more accurate in prediction postoperative survival for SCLC patients. Int J Surg 48: 83-85, 2017.
5. American Cancer Society: Cancer facts and figures 2015. American Cancer Society, Atlanta, GA, 2015. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2015/cancer-facts-and-figures-2015.pdf.
6. Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H and Straif K; International Agency for Research on Cancer Monograph Working Group IARC: The carcinogenicity of outdoor air pollution. Lancet Oncol 14: 1262-1263, 2013.
7. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.

8. Kenfield SA, Wei EK, Stampfer MJ, Rosner BA and Colditz GA: Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 17: 198-204, 2008.
9. Muscat JE, Stellman SD, Zhang ZF, Neugut AI and Wynder EL: Cigarette smoking and large cell carcinoma of the lung. Cancer Epidemiol Biomarkers Prev 6: 477-480, 1997.
10. Couraud S, Zalcman G, Milleron B, Morin F and Souquet PJ: Lung cancer in never smokers-a review. Eur J Cancer 48: 1299-1311, 2012.
11. Schaal C and Chellappan S: Nicotine-mediated regulation of nicotinic acetylcholine receptors in non-small cell lung adenocarcinoma by E2F1 and STAT1 transcription factors. PLoS One 11: e015645, 2016.
12. Cardinale A, Nastrucci C, Cesario A and Russo P: Nicotine: Specific role in angiogenesis, proliferation and apoptosis. Crit Rev Toxicol 42: 68-89, 2012.
13. Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D, *et al*: Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 124: 36-45, 2009.
14. Puisieux A, Brabletz T and Caramel J: Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 16: 488-494, 2014.
15. Improgo MR, Scofield MD, Tapper AR and Gardner PD: The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: Dual role in nicotine addiction and lung cancer. Prog Neurobiol 92: 212-226, 2010.
16. Sargent PB: The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 16: 403-443, 1993.
17. Lukas RJ, Changeux JP, Le Novère N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, *et al*: International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51: 397-401, 1999.
18. Dani JA and Bertrand D: Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxico 47: 699-729, 2007.
19. Papke RL, Bagdas D, Kulkarni AR, Gould T, AlSharari SD, Thakur GA and Damaj MI: The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor. Neuropharmacology 91: 34-42, 2015.
20. Arias HR, Richards VE, Ng D, Ghafoori ME, Le V and Mousa SA: Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol 41: 1441-1451, 2009.
21. Russo P and Taly A: α7-Nicotinic acetylcholine receptors: An old actor for new different roles. Curr Drug Targets 13: 574-578, 2012.
22. Egleton RD, Brown KC and Dasgupta P: Nicotinic acetylcholine receptors in cancer: Multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci 29: 151-158, 2008.
23. Zheng Y, Ritzenthaler JD, Roman J and Han S: Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol 37: 681-690, 2007.
24. Schuller HM: Regulatory role of the α7nAChR in cancer. Curr Drug Targets 13: 680-687, 2012.
25. Singh S, Pillai S and Chellappan S: Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J Oncol 2011: 456743, 2011.
26. Pillai S and Chellappan S: α7 nicotinic acetylcholine receptor subunit in angiogenesis and epithelial to mesenchymal transition. Curr Drug Targets 13: 671-679, 2012.
27. Zhang C, Ding XP, Zhao QN, Yang XJ, An SM, Wang H, Xu L, Zhu L and Chen HZ: Role of α7-nicotinic acetylcholine receptor in nicotine-induced invasion and epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. Oncotarget 7: 59199-59208, 2016.
28. Seifert U, Schlanstedt-Jahn U and Klug SJ: Screening for cancer. Internist (Berl) 56: 1114-1123, 2015.
29. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66: 271-289, 2016.
30. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E386, 2015.
31. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
32. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin 66: 115-132, 2016.
33. National Cancer Institute: SEER cancer statistics review, 1975-2011. https://seer.cancer.gov/archive/csr/1975_2011/. Updated December 17, 2014
34. Warren GW and Cummings KM: Tobacco and lung cancer: Risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book: 359-364, 2013.
35. Hecht SS: Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3: 733-744, 2003.
36. Whitrow MJ, Smith BJ, Pilotto LS, Pisaniello D and Nitschke M: Environmental exposure to carcinogens causing lung cancer: Epidemiological evidence from the medical literature. Respirology 8: 513-521, 2003.
37. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health: The health consequences of smoking-50 years of progress: A report of the surgeon general. Centers for Disease Control and Prevention (US), Atlanta, GA, 2014.
38. Jha P: Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer 9: 655-664, 2009.
39. Wessler I and Kirkpatrick CJ: Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. Br J Pharmacol 154: 1558-1571, 2008.
40. Cattaneo MG, D'Atri F and Vicentini LM: Mechanisms of mitogen-activated protein kinase activation by nicotine in small-cell lung carcinoma cells. Biochem J 328: 499-503, 1997.
41. Song P, Sekhon HS, Proskocil B, Blusztajn JK, Mark GP and Spindel ER: Synthesis of acetylcholine by lung cancer. Life Sci 72: 2159-2168, 2003.
42. Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, Gravett C, Mark GP, Grando SA and Spindel ER: M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 67: 3936-3944, 2007.
43. Zou W and Chen L: Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8: 467-477, 2008.
44. Song P, Sekhon HS, Fu XW, Maier M, Jia Y, Duan J, Proskosil BJ, Gravett C, Lindstrom J, Mark GP, *et al*: Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res 68: 4693-4700, 2008.
45. Song P, Sekhon HS, Jia Y, Keller JA, Blusztajn JK, Mark GP and Spindel ER: Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 63: 214-221, 2003.
46. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E and Chellappan S: Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci USA 103: 6332-6337, 2006.
47. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E and Chellappan S: Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 16: 2208-2217, 2006.
48. Lam DC, Girard L, Ramirez R, Chau WS, Suen WS, Sheridan S, Tin VP, Chung LP, Wong MP, Shay JW, *et al*: Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 67: 4638-4647, 2007.
49. Brown KC, Perry HE, Lau JK, Jones DV, Pulliam JF, Thornhill BA, Crabtree CM, Luo H, Chen YC and Dasgupta P: Nicotine induces the up-regulation of the α7-nicotinic receptor (α7-nAChR) in human squamous cell lung cancer cells via the Sp1/GATA protein pathway. J Biol Chem 288: 33049-33059, 2013.
50. Bordas A, Cedillo JL, Arnalich F Esteban-Rodriguez I, Guerra-Pastrián L, de Castro J, Martín-Sánchez C, Atienza G, Fernández-Capitan C, Rios JJ and Montiel C: Expression patterns for nicotinic acetylcholine receptor subunit genes in smoking-related lung cancers. Oncotarget 8: 67878-67890, 2017.
51. Paleari L, Catassi A, Ciarlo M, Cavalieri Z, Bruzzo C, Servent D, Cesario A, Chessa L, Cilli M, Piccardi F, *et al*: Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif 41: 936-959, 2008.
52. Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D and Chellappan S: Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One 4: e7524, 2009.

53. Medjber K, Freidja ML, Grelet S, Lorenzato M, Maouche K, Nawrocki-Raby B, Birembaut P, Polette M and Tournier JM: Role of nicotinic acetylcholine receptors in cell proliferation and tumour invasion in broncho-pulmonary carcinomas. Lung Cancer 87: 258-264, 2015.
54. Al-Wadei HA, Al-Wadei MH and Schuller HM: Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: A novel target for intervention. PLoS One 7: e29915, 2012.
55. Zovko A, Viktorsson K, Lewensohn R, Kološa K, Filipič M, Xing H, Kem WR, Paleari L and Turk T: APS8, a polymeric alkylpyridinium salt blocks α7 nAChR and induces apoptosis in non-small cell lung carcinoma. Mar Drugs 11: 2574-2594, 2013.
56. Paleari L, Sessa F, Catassi A, Servent D, Mourier G, Doria-Miglietta G, Ognio E, Cilli M, Dominioni L, Paolucci M, *et al*: Inhibition of non-neuronal alpha7-nicotinic receptor reduces tumorigenicity in A549 NSCLC xenografts. Int J Cancer 125: 199-211, 2009.
57. Grozio A, Paleari L, Catassi A, Servent D, Cilli M, Piccardi F, Paganuzzi M, Cesario A, Granone P, Mourier G and Russo P: Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: A promising prospective in anti-cancer drug development. Int J Cancer 122: 1911-1915, 2008.
58. Sheppard BJ, Williams M, Plummer HK and Schuller HM: Activation of voltage-operated Ca2+-channels in human small cell lung carcinoma by the tobacco-specific nitrosamine 4-(meth ylnitrosamino)-1-(3-pyridyl)-1-butanone. Int J Oncol 16: 513-518, 2000.
59. Jull BA, Plummer HK III and Schuller HM: Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol 127: 707-717, 2001.
60. Hung YH and Hung WC: 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) enhances invasiveness of lung cancer cells by up-regulating contactin-1 via the alpha7 nicotinic acetylcholine receptor/ERK signaling pathway. Chem Biol Interact 179: 154-159, 2009.
61. Zhong X, Fan Y, Ritzenthaler JD, Zhang W, Wang K, Zhou Q and Roman J: Novel link between prostaglandin E2 (PGE2) and cholinergic signaling in lung cancer: The role of c-Jun in PGE2-induced α7 nicotinic acetylcholine receptor expression and tumor cell proliferation. Thorac Cancer 6: 488-500, 2015.
62. Sun X, Ritzenthaler JD, Zhong X, Zheng Y, Roman J and Han S: Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha. Cancer Res 69: 6445-6453, 2009.
63. Chernyavsky AI, Shchepotin IB and Grando SA: Mechanisms of growth-promoting and tumor-protecting effects of epithelial nicotinic acetylcholine receptors. Int Immunopharmacol 29: 36-44, 2015.
64. Brown KC, Lau JK, Dom AM, Witte TR, Luo H, Crabtree CM, Shah YH, Shiflett BS, Marcelo AJ, Proper NA, *et al*: MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis 15: 99-114, 2012.
65. Shen J, Xu L, Owonikoko TK, Sun SY, Khuri FR, Curran WJ and Deng X: NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKCι/FAK loop. Cancer Lett 318: 106-113, 2012.
66. Iskandar AR, Miao B, Li X, Hu KQ, Liu C and Wang XD: β-cryptoxanthin reduced lung tumor multiplicity and inhibited lung cancer cell motility by downregulating nicotinic acetylcholine receptor α7 signalingg. Cancer Prev Res (Phila) 9: 875-886, 2016.
67. Zhang C, Yu P, Zhu L, Zhao Q, Lu X and Bo S: Blockade of α7 nicotinic acetylcholine receptors inhibit nicotine-induced tumor growth and vimentin expression in non-small cell lung cancer through MEK/ERK signaling way. Oncol Rep 38: 3309-3318, 2017.
68. Mucchietto V, Fasoli F, Pucci S, Moretti M, Benfante R, Maroli A, Di Lascio S, Bolchi C, Pallavicini M, Dowell C, *et al*: α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line. Br J Pharmacol, Jul 20, 2017 (Epub ahead of print).
69. Yan Y, Su C1, Hang M, Huang H, Zhao Y, Shao X and Bu X: Recombinant Newcastle disease virus rL-RVG enhances the apoptosis and inhibits the migration of A549 lung adenocarcinoma cells via regulating alpha 7 nicotinic acetylcholine receptors in vitro. Virol J 14: 190, 2017.
70. Paleari L, Cesario A, Fini M and Russo P: alpha7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma? Drug Discov Today 14: 822-836, 2009.
71. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
72. Cavallaro U and Christofori G: Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 50: 63-70, 2000.
73. Wu MY, Li CJ, Yiang GT, Cheng YL, Tsai AP, Hou YT, Ho YC, Hou MF and Chu PY: Molecular regulation of bone metastasis pathogenesis. Cell Physiol Biochem 46: 1423-1438, 2018.
74. Clark AG and Vignjevic DM: Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol 36: 13-22, 2015.
75. Shenker RF, McTyre ER, Ruiz J, Weaver KE, Cramer C, Alphonse-Sullivan NK, Farris M, Petty WJ, Bonomi MR, Watabe K, *et al*: The Effects of smoking status and smoking history on patients with brain metastases from lung cancer. Cancer Med 6: 944-952, 2017.
76. Warren GW, Sobus S and Gritz ER: The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol 15: e568-e580, 2014.
77. Gopalakrishna R, Chen ZH and Gundimeda U: Tobacco smoke tumor promoters, catechol and hydroquinone, induce oxidative regulation of protein kinase C and influence invasion and metastasis of lung carcinoma cells. Proc Natl Acad Sci USA 91: 12233-12237, 1994.
78. Yoshino I and Maehara Y: Impact of smoking status on the biological behavior of lung cancer. Surg Today 37: 725-734, 2007.
79. Schuller HM: Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. Prog Exp Tumor Res 39: 45-63, 2007.